Page 108
The Willner Window Product Reference Catalog, Spring, 2013
since 1911
• Willner Chemists •
the nutritional supplement professionals
Genuine Health
Asenta
period after the baseline visit was 44 days.
After this period, restitution to balanced vagi-
nal microbiota was reported in 40 subjects
(26.9%) in the placebo group, compared to
243 subjects (61.5%) in the probiotic group.
Differences between groups were statistically
significant at p<0.001. After the additional 6
weeks of follow up, normal vaginal microbio-
ta were still present in more than half
(51.1%) of subjects in the probiotic group,
but only in around one-fifth (20.8%) of sub-
jects who were taking placebo (p<0.001).
The conclusion is that “oral probiotics
could be an alternative, side effect-free treat-
ment for one of the most common indica-
tions in gynecology, combining the good
aspects of both metronidazole and vaginal
capsules.”
In a related study, presented by Dr. Gaby in
his book, Nutritional Medicine, similar posi-
tive results were shown, when combined
with oral metronidazole therapy:
One hundred twenty-five women with bac-
terial vaginosis were treated with oral
metronidazole (500 mg twice a day for 7
days), and were randomly assigned to
receive, in double-blind fashion, 1 capsule
twice a day of the combination of L. rham-
nosus GR-1 and L. reuteri RC-14 or placebo
for 30 days, beginning with the start of
metronidazole therapy. Each capsule con-
tained 109 viable cells of each strain. The
probiotics were taken at least 1 hour after
the antibiotic. Cure was defined as a normal
Nugent score, a negative sialidase test, and
no symptoms or signs of bacterial vaginosis at
day 30. The cure rate was significantly higher
in the active-treatment group than in the
placebo group (88% vs. 40%; p < 0.001).
(Anukam K, Osazuwa E, Ahonkhai I, et al.
Augmentation of antimicrobial metronidazole
therapy of bacterial vaginosis with oral probi-
otic Lactobacillus rhamnosus GR-1 and
Lactobacillus reuteri RC-14: randomized,
double-blind, placebo controlled trial.
Microbes Infect 2006;8:1450–1454.)
. . . continued from page 92
fem-dophilus®, by Jarrow Formulas, contains two patented and clinically documented probiotic strains, Lactobacillus
rhamnosus, GR-1®and Lactobacillus reuteri, RC-14®, discovered and developed by Dr. Reid and Dr. Bruce at Urex
Biotech. Over 20 years of research supports the oral use of GR-1®and RC-14® to colonize and protect the vaginal tract.*
Clinical trials have shown that GR-1® and RC-14®: • Help to maintain or restore healthy vaginal flora that are impor-
tant in maintaining vaginal health* • Support the health of the urinary tract*
fem-dophilus® is manufactured under pharmaceutical GMP conditions insuring potency and consistency. The probiotic
strains in fem-dophilus® are in a proprietary polysaccharide matrix, which protects the bacteria from stomach acid and
enhances probiotic bacteria survival to the lower intestine.*
Willner Chemists Product Code: # 55615, 60 Capsules
Omega-3
made
easy.
Save 25
%
on
all NutraSea
products.
April 4–May 21
ascentahealth.com
Delicious. Creamy. Smooth.
Vegan
proteins+
natural
strawberry vanilla smoothie
Genuine Health has joined a community that is
redefning the way the world does business -
as a Certifed B Corporation!
Learn more about Genuine Health’s commitment to quality, effcacy, and
sustainability and BCorp certifcation at
genuinehealth.com |
HORIZONTAL-B
The horizontal-B version is an alternate
horizontal format and should only be
used when legibility is an issue.
Delicious. Creamy. Smooth.
proteins+ natural
strawberry vanilla smoothie
Genuine Health has joined a community that is
A unique combination of easy to digest
non-GMO vegan protein sources including:
potato protein isolate, yellow pea protein isolate,
sprouted brown rice, alfalfa juice & hemp proteins.
This innovative and nourishing formula
provides a 100% vegetarian protein blend,
rich in all essential amino acids.
Absolutely delicious, with zero sugar.